| Oct 4 |
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
|
| Sep 18 |
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket
|
| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
| Sep 14 |
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
|
| Sep 2 |
IO Biotech’s melanoma treatment trial to continue after IDMC review
|
| Aug 30 |
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
|
| Aug 26 |
IO Biotech Announces Participation in Upcoming Investor Conferences
|
| Aug 13 |
IO Biotech GAAP EPS of -$0.31
|
| Aug 13 |
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
|
| Jul 25 |
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
|
